A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide.

Keiko YamaokaShuichi NagashimaNobukazu OkadaNagisa SawayamaShinsuke SaitoManabu TakahashiKenta OkadaKazuhiro EndoMasaru KoizumiHideki SasanumaKen EbiharaAtsuko KasajimaNoriyoshi FukushimaNaohiro SataShun Ishibashi

Published in: Clinical case reports (2021)

Long-acting somatostatin analogs, including lanreotide slow release (LAN-SR) and octreotide long-acting release (OCT-LAR), can improve hypoglycemia in insulinoma. LAN-SR may be more beneficial in some patients with insulinoma than OCT-LAR.

Keyphrases

neuroendocrine tumors
type diabetes
optical coherence tomography
diabetic retinopathy
glycemic control
molecular docking
skeletal muscle
insulin resistance
molecular dynamics simulations